This systematic review and meta-analysis is the first to evaluate the evidence for an
association between metformin use and cancer outcomes in patients undergoing treatment …

Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase
(HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of …

Obesity is associated with a range of health outcomes that are of clinical and public health
significance, including cancer. Herein, we summarize epidemiologic and preclinical …

Statins are widely used in the evidence-based lowering of cardiovascular disease (CVD)
risk. The use of these drugs for secondary prevention of CVD is well founded, but their …

An increasing amount of data supports an inverse association between statin use and
cancer risk. The findings for prostate cancer, particularly advanced disease, are the most …

Statins have shown antineoplastic properties in preclinical studies with breast cancer cells.
They inhibit the enzyme “HMG CoA reductase” and the expression of this enzyme in cancer …

Importance Statin use has been associated with improved prostate cancer outcomes.
Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for …

Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which
is a rate-limiting enzyme in the mevalonate pathway. The pleiotropic effects of statins may be …

Statins are well known competitive inhibitors of hydroxymethylglutaryl-CoA reductase
enzyme (HMG-CoA reductase), thus traditionally used as cholesterol-lowering agents. In …

Background: Preclinical evidence from lung cancer cell lines and animal models suggest
that statins could have anticancer properties. We investigated whether statin users had …